Publication:
Efficacy and safety of prolonged versus intermittent infusion of beta-lactam antibiotics as empirical therapy in patients with sepsis

0
0

Issued Date

2019

Resource Type

Article

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-85062901646

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 102, No.2 (2019), p.129-135

Suggested Citation

Hemvimon S., Srinithiwat P., Koomanachai P., Thamlikitkul V., Jitmuang A. Efficacy and safety of prolonged versus intermittent infusion of beta-lactam antibiotics as empirical therapy in patients with sepsis. Journal of the Medical Association of Thailand. Vol 102, No.2 (2019), p.129-135. Retrieved from: https://hdl.handle.net/20.500.14740/5478

Title

Efficacy and safety of prolonged versus intermittent infusion of beta-lactam antibiotics as empirical therapy in patients with sepsis

Author(s)

Hemvimon S.
 Srinithiwat P.
 Koomanachai P.
 Thamlikitkul V.
 Jitmuang A.

Abstract

Objective: To determine the efficacy and safety of beta-lactam antibiotics (ceftazidime, cefepime, piperacillin/tazobactam, imipenem, meropenem, and doripenem) administered by intermittent infusion (II) compared with three to four-hour prolonged infusion (PI) in acutely ill-hospitalized patients with sepsis. Materials and Methods: The authors conducted a prospective cohort study between January 2010 and December 2013. Results: Of 219 subjects, 213 were recruited in the present study, 109 patients were in the II group and 104 patients were in the PI group. No significant difference of baseline characteristics between both groups. About 70% of infections from both groups were associated with hospital-associated infection. Sepsis was significantly higher in PI group (p=0.02). Pneumonia, bacteremia, and urinary tract infection (UTI) were the major foci of sepsis in the present study. Escherichia coli that mainly came from UTI was the major etiologic pathogen, whereas the causative pathogen was unknown in 49.3%. The 28-day survival was 87.2% in the II group and 79.8% in the PI group (p=0.27). Favorable clinical outcomes resulted in 74.3% of the II group and 76.9% of the PI group (p=0.11). A complete microbiological response was documented in 62.3% of the II group and 63.2% of the PI group (p=0.91). No serious adverse events were observed in either group. Conclusion: There were no significant differences in clinical, microbiological, and safety outcomes between the two groups. © Journal of the medical association of Thailand.

Subject(s)

Amoxicillin plus clavulanic acid
 Ceftazidime
 Imipenem
 Meropenem
 Piperacillin plus tazobactam
 Vancomycin
 Beta lactam antibiotic
 Cefepime
 Ceftazidime
 Doripenem
 Imipenem
 Meropenem
 Piperacillin plus tazobactam
 Acinetobacter baumannii
 Adult
 Aged
 Article
 Controlled study
 Coronary artery disease
 Diabetes mellitus
 Diarrhea
 Escherichia coli
 Female
 Human
 Klebsiella pneumoniae
 Major clinical study
 Male
 Minimum inhibitory concentration
 Observational study
 Randomized controlled trial (topic)
 Sepsis
 Urinary tract infection
 APACHE
 Bacteremia
 Bacterial clearance
 Clinical outcome
 Cohort analysis
 Comparative study
 Continuous infusion
 Drug efficacy
 Drug infusion
 Drug intermittent therapy
 Drug safety
 Empirical research
 Extended spectrum beta lactamase producing Escherichia coli
 Extended spectrum beta lactamase producing Klebsiella pneumoniae
 Gastrointestinal symptom
 Hospital infection
 Infection
 Intra abdominal infection
 Long term exposure
 Middle aged
 Outcome assessment
 Phlebitis
 Pneumonia
 Prospective study
 Pseudomonas aeruginosa
 Rash
 Sepsis
 Skin and soft tissue infection
 Survival rate
 Treatment response

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/5478

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By